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Abstract Dietary intake of linoleic acid (LNA, 18:2n-6)
has increased dramatically during the 20th century and is
associated with greater prevalence of obesity. The endo-
cannabinoid system is involved in regulation of energy bal-
ance and a sustained hyperactivity of the endocannabinoid
system may contribute to obesity. Arachidonic acid (ARA,
20:4n-6) is the precursor for 2-AG and anandamide (AEA),
and we sought to determine if low fat diets (LFD) could be
made obesogenic by increasing the endocannabinoid pre-
cursor pool of ARA, causing excessive endocannabinoid
signaling leading to weight gain and a metabolic profile
associated with obesity. Mice (C57BL/6j, 6 weeks of age)
were fed 1 en% LNA and 8 en% LNA in low fat (12.5 en%)
and medium fat diets (MFD, 35 en%) for 16 weeks. We
found that increasing dietary LNA from 1 to 8 en% in LFD
and MFD significantly increased ARA in phospholipids
(ARA–PL), elevated 2-AG and AEA in liver, elevated
plasma leptin, and resulted in larger adipocytes and more
macrophage infiltration in adipose tissue. In LFD, dietary
LNA of 8 en% increased feed efficiency and caused greater
weight gain than in an isocaloric reduction to 1 en% LNA.
Increasing dietary LNA from 1 to 8 en% elevates liver
endocannabinoid levels and increases the risk of developing
obesity. Thus a high dietary content of LNA (8 en%)
increases the adipogenic properties of a low fat diet.
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Abbreviations
2-AG Arachidonoylglycerol
ARA Arachidonic acid
AEA Anandamide
CB Cannabinoid receptor
DHA Docosahexaenoic acid
en% Percent of energy
EPA Eicosapentaenoic acid
eWAT Epididymal white adipose tissue
HUFA Highly unsaturated fatty acid(s) (fatty acids of
[20 carbon length)
iWAT Inguinal white adipose tissue
LFD Low fat diet
LNA Linoleic acid
MFD Medium fat diet
MUFA Monounsaturated fatty acid(s)
PL Phospholipids
RBC Red blood cells
SFA Saturated fatty acid(s)
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arachidonoylethanolamine (anandamide or AEA) [1–4] and
the cannabinoid receptors (CB1 and CB2) [5, 6]. Genetic
and pharmacologic impairment of the CB1 receptor have
demonstrated the role of the endocannabinoid system in
energy homeostasis by inhibiting food intake and reducing
body weight, both occurring independent of energy intake
[7–9]. Activation of the cannabinoid receptor CB1 by
endocannabinoids or exogenous agonists, centrally and
peripherally, favors metabolic processes that stimulate
appetite, increase food intake, activates fat storage path-
ways and down regulates catabolism resulting in adipose
accretion [7, 10]. In the liver, CB1 activation increases de
novo lipogenesis through stimulation of fatty acid synthase
activity leading to fatty liver and obesity [10]. Under
normal circumstances the endocannabinoid system is only
activated on demand in response to acute stimulation, but
has been found to be tonically overactivated in animal
models of genetic and diet-induced obesity [10–15]. Down
regulation of excessive endocannabinoid system activity is
being actively pursued to reduce obesity [16]. Because
pharmacological blockade of the CB1 receptor is effective
in treating obesity and related metabolic derangements [17,
18], a dietary approach to diminish endocannabinoid
hyperactivity may represent a safer alternative than phar-
maceuticals [19, 20]. In this study, we are addressing an
underlying cause of endocannabinoid overactivation that
can potentially be translated into a safe alternative to pre-
vent human obesity.
Current dietary guidelines recommend the replacement
of saturated fat with polyunsaturated fat to reduce the
incidence of cardiovascular disease [21, 22], and have
increased the consumption of vegetable oils. The estimated
per capita consumption of soybean oil, one of the major
dietary sources of LNA in the US, has increased more than
1,000-fold from 1909 to 1999, increasing the availability of
LNA from 2.8 to 7.2 en% [23]. We previously reported a
robust positive correlation between the prevalence of
obesity in the US and soybean oil, and with the other pri-
mary sources of LNA such as poultry and shortening [14].
Thus we believe that the high intake of LNA, of which
soybean oil is the greatest contributor in the US diet, is a
strong contributor to the obesity epidemic.
The endocannabinoids are endogenous lipid mediators
formed from the pool of 20 carbon n-6 fatty acids present
in membrane phospholipids (PL) [24]. The n-6 fatty acid
arachidonic acid (ARA, 20:4n-6) in phospholipids is the
precursors of the two best characterized endocannabinoids
2-AG and AEA. Since n-3 and n-6 fatty acids cannot be
synthesized de novo the fatty acid composition in tissues is
reflected by the dietary intake of these fatty acids [25]. An
epidemiological report linked increasing intake of LNA
over time to increased prevalence of obesity and postulated
that ARA-induced elevation in 2-AG may have altered the
energy balance towards obesity [26]. In a recent study we
modeled the increase in human consumption of LNA and
demonstrated that increasing dietary levels of LNA from 1
to 8 en%, elevated the levels of ARA–PL, 2-AG and AEA
in liver and promoted obesity in mice fed high fat diets of
35 and 60 en% fat [14]. We showed that it was the n-3 and
n-6 fat composition of the diets, rather than the total
amount of fat that determined the obesogenic properties of
the diets [14]. In the same study, we also reversed the
obesogenic effect of high fat diets by isocalorically
decreasing dietary LNA from 8 to 1 en% and attenuated
the ARA-dependent excessive endocannabinoid activity
[14]. Furthermore, we demonstrated that reducing the
ARA–PL precursor pool by adding 1 en% eicosapentae-
noic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA,
22:6n-3) to 8 en% LNA diets reversed both stimulation of
endocannabinoid activity and the obesogenic effect of high
fat diets [14]. Thus, the obesogenic potential of high fat
diets can be reversed by selectively reducing the essential
fatty acid precursors of endocannabinoids available only
from dietary sources. As we have previously shown that
8 en% LNA elevate endocannabinoid levels and induce
adiposity in high fat diets, we sought to investigate whether
a low fat diet could be made obesogenic by similar ele-
vations of dietary endocannabinoid precursors. Therefore
we aimed to determine if selective isocaloric inclusion of
8 en% LNA in a low fat diet (12.5 en%) and medium fat
diet (35 en%) resulted in endocannabinoid hyperactivity
and obesity.
Materials and Methods
Ethical Statement
All animal experiments were approved by the National
Animal Health Authorities (Norwegian approval identifi-
cation 1973). Care and handling were in accordance with
local institutional recommendations and rules, and no
adverse events were observed. The animals were anesthe-
tized with isoflurane to minimize suffering before
decapitation.
Animals
Male mice (n = 36), 6 weeks of age (C57BL/6j, Taconic,
Denmark) were randomly assigned to four experimental
diets (n = 9) (Table 1) and housed individually. The
animals were maintained on a 12:12 h light–dark cycle at
29 ± 1 C. All animals were sacrificed at 22 weeks of
age.
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Water and Food
Food provided as pellets was available ad libitum for
16 weeks. The diets contained 12.5 en% fat (LFD) and
35 en% fat (MFD) and 18 and 22 en% protein from casein
(LFD and MFD respectively). Dextrin was used as a neu-
tral source of carbohydrate, and was used to compensate
for the lower fat content in the LFDs. In order to model the
increase in human consumption of LNA from 1 to 8 en%
and isolate LNA and ALA as controlled variables different
oils were mixed to obtain the specific fatty acid profile of
the diets listed in Table 1. Food intake was measured every
other day by weighing each food cup and spillage and
subtracting the previously collected weight. Body weight
was recorded once a week for all animals.
Endocannabinoids
Mice were sacrificed by decapitation and brain and liver
were quickly snap-frozen in liquid nitrogen. The 2-AG and
AEA were extracted and determined by gas chromatogra-
phy/mass spectrometry/mass spectrometry (GC/MS/MS) as
previously described [14].
Fatty Acid Profile
Liver, red blood cells (RBC) and adipose tissue lipids were
extracted with chloroform: methanol (2:1 v/v) and phos-
pholipids were separated from neutral lipids by solid phase
extraction (SPE). Epididymal adipose tissue (eWAT) and
liver lipids were evaporated to dryness and recovered in
chloroform to a concentration of 50 mg/mL lipids. An
aliquot of 200 lL (10 mg lipids) was applied to a SPE
column (Isolute). RBC lipids were evaporated to dryness
and recovered with three washings of 100 mL chloroform
and deposited to the SPE column. Neutral lipids were
eluted with 10 mL chloroform/methanol (98:2 v/v) and
polar lipids were eluted with 20 mL methanol. The fatty
acid composition in the phospholipid fraction of liver and
RBC, and the neutral fraction of adipose tissue were ana-
lyzed by GC as previously described [27].
Blood Chemistry
Blood was collected in an Eppendorf tube from the
bleeding carcass after decapitation and separated into
erythrocytes and plasma. Plasma hormone levels were
determined using commercially available ELISA kits in
accordance with manufacturer’s instructions for insulin
(DRG Diagnostics, Ultrasensitive ELISA, mouse, detection
limit 0.025 lg/L, coefficient of variation within assay
*2 %, between assay *4 %), leptin (ALPCO Immuno-
assays, Leptin (Mouse/Rat) ELISA, range 15–1,600 pg/
mL, sensitivity 10 pg/mL, inter-assay and intra-assay var-
iation coefficients \4.7 and \4.4 %, respectively) and
adiponectin (ALPCO Immunoassays (Mouse) Total, HMW
ELISA, range 0.125–8 ng/mL, sensitivity 0.032 ng/mL,
inter-assay and intra-assay coefficient of variation
*3.5 %.).
Histology
Sections of adipose tissue were fixed in 4 % formaldehyde
in 0,1 M phosphate buffer (PB) for 24 h, washed in PB,
dehydrated in ethanol, and embedded in paraffin after
clearing with xylene. 5 lm thick sections of the embedded
Table 1 Diet composition and fatty acid profile of diets
Low fat diets
(12.5 en%)
Medium fat diets
(35 en%)
1 en%
LNA
8 en%
LNA
1 en%
LNA
8 en%
LNA
g/kg
Cocosa (coconut oil) 3 – 129 85
Safflower oil 1 44 – 42
Olive oil 44 – 33 31
Flaxseed oil 2 6 3 7
Total oil added (g/kg) 50 50 165 165
% energy derived from
Fat 11 11 32 34
Carbohydrate 71 71 45 44
Protein 18 18 23 22
(% of energy)
Sum SFA 2.5 1.5 25 17
Sum MUFA 9 2 7 8
18:2n-6 1 8 1 8
20:4n-6 – – – –
Sum n-6 1 8 1 8
18:3n-3 0.3 0.9 0.4 1
20:5n-3 – – – –
22:6n-3 – – – –
Sum n-3 0.3 0.9 0.3 1
Total n-6/n-3 ratio 3 9 3 8
Estimated n-6 HUFA1 (%) 56 72 53 72
Estimated Omega-3 Index2 11 5 11.5 5.5
All diets were supplemented with 60 mg/k ethoxyquin, 2.5 g/kg
choline bitartrate, 3 g/kg L-cystein, 13 g/kg vitamin mix, 47 g/kg
mineral mix, 50 g/kg sucrose, 50 g/kg cellulose, 100 g/kg corn starch.
Energy (kcal) of diets; LF diets; 3,900, MF diets; 4,500
LNA linoleic acid, SFA saturated fatty acids, MUFA monounsaturated
fatty acids, HUFA highly unsaturated fatty acids ([20 carbon)
1 Calculated from the Lands equation [25], n-3 HUFA = 100 - n-6
HUFA
2 Omega-3 index: (omega-3 HUFA 9 0.32) - 3.5 [28, 59]
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tissue were stained with eosin and hematoxylin. Sections
were visually examined using an Olympus BX 51 binocular
microscope (Tokyo, Japan) fitted with a Nikon DS-Fi1
camera (Digital Sight DS-Fi1, Nikon, Japan). Adipocyte
size was measured using the interactive measurement
module of an image analysis system equipped with an
Olympus microscope, a Nikon DS-Fi1 camera and NIS-
elements software (Nikon, Japan). Two hundred adipo-
cytes per tissue (n = 2) were randomly selected and their
size was measured by drawing a horizontal line between
the cell membranes.
Immunohistochemistry
Samples were processed in formaldehyde as described
above. Then 5-lm sections were deparaffinized, rehy-
drated, and endogenous peroxide was inactivated (3 %
hydrogen peroxide). To reduce non-specific staining the
sections were incubated in heat-inactivated normal goat
serum (10 %, 10 min). Sections were then incubated
overnight at 4 C with rat anti-mouse F4/80 (1:500; Sero-
tec, Germany), subsequently washed in tris buffered saline
(TBS, 3 times, 10 min) and incubated with HRP-conju-
gated goat anti-rat IgG (1:250; Serotec, Germany) for 2 h.
After washing in TBS (3 9 10 min) specific binding was
visualized using diamino benzidine. The immunohisto-
chemistry was performed and examined by a scientist
masked to the experimental conditions.
Statistics
All data are analyzed using StatSoft, Inc. (2009) STAT-
ISTICA (data analysis software system), version 9.0. Data
were analyzed for homogeneity of variance (Levene’s test)
and one-way ANOVA, with Fisher LSD post hoc test when
p \ 0.05. Data are presented as mean ± standard error of
the mean (SEM).
Results
Dietary LNA Increased Tissue Arachidonic Acid
and Endocannabinoid Levels
Diets containing 8 en%, reflecting current US intake,
resulted in significantly higher amounts of LNA and ARA
in RBC–PL (Table 2), liver–PL (Table 3), and eWAT
(Table 4) compared to diets containing 1 en% LNA.
Consequently, elevating LNA from 1 to 8 en% in both
LFD and MFD significantly increased 2-AG and AEA in
liver (Fig. 1a, b). The brain is less influenced by dietary
manipulation and we found no differences in endocan-
nabinoid levels in the cerebral cortex (Fig. 1c, d).
Elevating dietary LNA from 1 to 8 en% significantly
reduced EPA–PL in both RBC (Table 2) and liver
(Table 3). The concentration of DHA–PL was increased in
RBC of mice fed LFD and MFD containing 1 en% LNA
(Table 2), but only in livers of mice fed LFD 1 en%
(Table 3). Thus, increasing dietary LNA from 1 to 8 en%
decreased the n-3 index in RBC-PL from 9 to 5 (Table 2).
Mice fed 8 en% LNA had significantly higher EPA and
DHA in eWAT than mice fed 1 en% LNA in both LFD and
MFD (Table 4).
Dietary LNA Increased Weight Gain and Body Weight
in Low Fat Diets
Food intake was not affected by the dietary treatments
(Table 5). As expected, mice fed MFDs gained more body
weight and tended to accumulate more adipose tissue than
mice fed an LFD when dietary LNA was kept low at 1 en%
Table 2 Fatty acid profile in RBC-PL [lg FA/g RBC, (w.w.)]
FA (lg/g) Low fat (12 en% fat) Medium fat (35 en% fat)
1 en%
LNA
8 en%
LNA
1 en% LNA 8 en%
LNA
16:0 529 ± 19a 590 ± 11b 578 ± 21ab 585 ± 18b
18:0 172 ± 7a 246 ± 8b 228 ± 9b 271 ± 9c
Sum SFA 718 ± 26a 858 ± 19b 840 ± 30b 887 ± 28b
18:1n9 395 ± 13a 204 ± 5b 375 ± 12a 347 ± 7c
Sum
MUFA
518 ± 16a 287 ± 7b 503 ± 16a 323 ± 9c
18:2n-6 111 ± 6a 272 ± 8b 158 ± 6c 291 ± 11b
20:4n-6 293 ± 11a 407 ± 8b 324 ± 15a 404 ± 12b
22:5n-6 11.2 ± 0.4a 16.3 ± 0.4b 12.4 ± 0.6a 16.9 ± 0.8b
Sum n-6 497 ± 17a 775 ± 15b 557 ± 20c 791 ± 29b
18:3n-3 3.3 ± 0.4a 2.8 ± 0.1a 4.7 ± 0.3b 2.1 ± 0.1c
20:5n-3 19.6 ± 1.3a 7.4 ± 0.4b 19.8 ± 0.7a 8.9 ± 0.4b
22:5n-3 14.6 ± 0.9a 18.1 ± 0.6b 18.6 ± 0.9b 18.2 ± 0.7b
22:6n-3 179 ± 7ab 164 ± 4ac 180 ± 7b 158 ± 3c
Sum n-3 220 ± 9a 193 ± 5b 228 ± 8a 188 ± 4b
n-6/n-3
ratio
2.1 ± 0.0a 4.0 ± 0.1b 2.5 ± 0.0c 4.2 ± 0.1d
n-6 HUFA
(%)
62 ± 0a 73 ± 0b 64 ± 1c 73 ± 0b
n-3 HUFA
(%)
38 ± 0a 27 ± 0b 34 ± 1c 27 ± 0b
Omega-3
Index
9 ± 0a 5 ± 0b 8 ± 0c 5 ± 0b
Different superscript letters indicate significant statistical differences,
Mann–Whitney p \ 0.01, n = 8–9. Omega-3 Index is calculated
from (n-3 HUFA 9 0.32) - 3.5 [28, 59]). Tissue levels of n-6 HUFA
is in good concurrency with estimated n-6 HUFA values in Table 1
LNA linoleic acid, SFA saturated fatty acids, MUFA monounsaturated
fatty acids, HUFA highly unsaturated fatty acids
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(Fig. 2, Table 5). Of note, when dietary LNA was elevated
from 1 to 8 en% in the low fat diet, feed efficiency
increased resulting in a similar weight gain and body
weight as the MFDs (Fig. 2, Table 5). Muscle weight did
not differ between the groups (data not shown), indicating
that differences in body weight was due to accumulation of
adipose tissue and not lean mass.
Dietary LNA Elevated Plasma Leptin Levels
The LFD and MFD containing 8 en% LNA significantly
elevated plasma leptin concentrations compared to 1 en%
LNA diets (Table 5). Mice fed LFDs of 1 and 8 en% LNA
had similar plasma adiponectin levels per gram fat as mice
fed 8 en% LNA in the MFD and significantly higher body
fat levels than mice fed 1 en% in the MFD (Table 5).
Plasma insulin concentrations were not affected by the
dietary treatments (Table 5).
Dietary LNA Increased Adipose Accumulation
and Adipocyte Size
The accumulation of white adipose tissue (WAT) and the
adiposity index [(subcutaneous ? retroperitoneal ? ingui-
nal fat pads)/eviscerated body weight 9 100] was similar in
mice fed 8 en% LNA in an LFD and mice fed the MFDs
(Table 5). Mice fed 1 en% LNA in the LFD had significantly
less adipose tissue and lower adiposity index than mice fed
8 en% LNA in a MFD (Table 5). We performed immuno-
histochemical analysis of adipose tissue by staining for the
MI macrophage marker F4/80. We only found macrophage
infiltration in eWAT of mice fed 8 en% LNA diets inducing
F4/80 positive macrophages forming crown-like structures
around adipocytes (Fig. 3a). No macrophage infiltration was
found in iWAT (data not shown). These results indicate that
the composition of dietary fat is substantially more important
than the total amount of fat in determining adipose tissue
accumulation and macrophage infiltration (Fig. 3a, b).
Table 3 Fatty acid profile in
liver-PL [mg FA/g liver (w.w.)]
Different superscript letters
indicate significant statistical
differences, Mann–Whitney
p \ 0.01, n = 8–9
LNA linoleic acid, SFA
saturated fatty acids, MUFA
monounsaturated fatty acids,
HUFA highly unsaturated fatty
acids
FA (mg/g) Low fat (12 en% fat) Medium fat (35 en% fat)
1 en% LNA 8 en% LNA 1 en% LNA 8 en% LNA
16:0 3.6 ± 0.2 3.4 ± 0.3 3.4 ± 3.2 3.5 ± 0.1
18:0 2.0 ± 0.1a 2.3 ± 01ab 2.1 ± 0.1a 2.5 ± 0.1b
Sum SFA 5.8 ± 0.3 5.8 ± 0.4 5.6 ± 0.3 6.2 ± 0.2
18:1n-9 2.9 ± 0.1a 1.2 ± 0.1b 2.2 ± 0.1c 1.3 ± 0.1b
Sum MUFA 4.5 ± 0.1a 2.0 ± 0.2b 3.6 ± 0.2c 2.1 ± 0.11b
18:2n-6 1.2 ± 0.1a 2.3 ± 0.2b 1.0 ± 0.1a 2.2 ± 0.1b
20:4n-6 1.9 ± 0.1a 3.1 ± 0.2b 1.8 ± 0.1a 3.2 ± 0.2b
Sum n-6 3.5 ± 0.2a 5.9 ± 0.5b 3.6 ± 0.2a 6.0 ± 0.3b
20:5n-3 0.14 ± 0.02a 0.09 ± 0.01b 0.12 ± 0.01ab 0.10 ± 0.00b
22:5n-3 0.07 ± 0.02a 0.09 ± 0.01ab 0.09 ± 0.01ab 0.10 ± 0.00b
22:6n-3 2.4 ± 0.1a 1.9 ± 0.3b 2.0 ± 0.1b 1.9 ± 0.1b
Sum n-3 2.6 ± 0.2a 2.1 ± 0.2b 2.2 ± 0.1ab 2.1 ± 0.1b
n-6/n-3 ratio 1.4 ± 0.01a 2.8 ± 0.1b 1.5 ± 0.1a 2.9 ± 0.1b
n-6 HUFA (%) 47 ± 1a 62 ± 1b 50 ± 1a 64 ± 1b
Table 4 Fatty acid profile in neutral lipids of white epididymal
adipose tissue [mg FA/g eWAT (w.w.)]
FA (mg/g) Low fat (12 en% fat) Medium fat (35 en% fat)
1 en%
LNA
8 en%
LNA
1 en%
LNA
8 en%
LNA
16:0 133 ± 3ac 158 ± 3b 149 ± 3bc 140 ± 5c
18:0 8.3 ± 0.3a 12.5 ± 0.4b 8.3 ± 0.2a 10.5 ± 0.5c
Sum SFA 163 ± 4a 189 ± 4b 297 ± 4c 268 ± 13d
18:1n9 489 ± 5a 236 ± 5b 360 ± 4c 301 ± 6d
Sum MUFA 614 ± 6a 333 ± 6b 497 ± 4c 393 ± 9d
18:2n-6 57 ± 3a 308 ± 3b 42 ± 3c 187 ± 4d
20:4n-6 1.1 ± 0.0a 4.0 ± 0.2b 0.8 ± 0.0a 2.6 ± 0.1c
22:5n-6 0.1 ± 0.0a 0.4 ± 0.1b 0.0 ± 0.0a 0.2 ± 0.1c
Sum n-6 59 ± 3a 317 ± 3b 43 ± 3c 192 ± 4d
18:3n-3 5.8 ± 0.2a 19.1 ± 0.4b 4.4 ± 0.1c 12.1 ± 0.2d
20:5n-3 0.1 ± 0.0a 0.4 ± 0.0b 0.1 ± 0.0a 0.3 ± 0.0c
22:5n-3 0.2 ± 0.0a 0.7 ± 0.1b 0.2 ± 0.0a 0.5 ± 0.0c
22:6n-3 1.5 ± 0.1a 2.5 ± 0.1b 1.1 ± 0.1c 1.7 ± 0.1a
Sum n-3 8.9 ± 0.2a 23.5 ± 0.5b 7.2 ± 0.1c 14.8 ± 0.3d
n-6/n-3 ratio 6.7 ± 0.3a 13.6 ± 0.3b 6.0 ± 0.4a 13.1 ± 0.3b
n-6 HUFA
(%)
49 ± 1a 69 ± 0b 46 ± 2a 67 ± 1b
Different superscript letters indicate significant statistical differences,
Mann–Whitney p \ 0.01, n = 8–9
LNA linoleic acid, SFA saturated fatty acids, MUFA monounsaturated
fatty acids, HUFA highly unsaturated fatty acids
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Discussion
We have previously shown that modeling the increase in
human consumption of dietary LNA from 1 to 8 en% LNA
during the last century [23] caused excessive endocan-
nabinoid levels and also induces obesity in mice fed diets
of 35 and 60 en% fat [14]. To our knowledge, we dem-
onstrate here for the first time that an LFD can be made
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Fig. 1 Selective elevation of dietary LNA elevates liver endocan-
nabinoids in mice fed low fat diets (LFD) of 12.5 en% fat (light gray)
and medium fat diets (MFD) of 35 en% fat (dark gray). Increasing
dietary LNA from 1 en% (open bars) to 8 en% (hatched bars) in both
LFD and MFD elevated (a) liver 2-AG and (b) AEA, an increase that
was not observed in the cerebral cortex (c, d). Different superscript
letters indicate a statistical significance p \ 0.05 by ANOVA,
n = 8–9
Table 5 Physical and biochemical parameters
Parameter Low fat (12 en% fat) Medium fat (35 en% fat)
1 en% LNA 8 en% LNA 1 en% LNA 8 en% LNA
Total food intake (g/112 days) 357 ± 8a 361 ± 10a 322 ± 7b 323 ± 5b
Total caloric intake (kcal) 1,398 ± 33 1,443 ± 39 1,387 ± 28 1,361 ± 19
Feed efficiency (BW gain/mcal) 5.6 ± 0.5a 8.1 ± 0.8b 9.7 ± 0.5b 9.8 ± 0.8b
Body weight at start (g) 25.8 ± 0.8 25.9 ± 0.5 25.9 ± 0.6 25.8 ± 0.5
Final body weight (g) 33.7 ± 1.1a 37.8 ± 1.7b 39.4 ± 1.1b 39.2 ± 1.5b
Weight gain (g) 7.9 ± 0.8a 11.9 ± 1.4b 13.5 ± 0.9b 13.4 ± 1.2b
WAT (g) 1.8 ± 0.3a 2.4 ± 0.3a,b 2.4 ± 0.3a,b 2.8 ± 0.3b
Adiposity Index (%) 5.9 ± 0.9a 7.5 ± 0.7ab 7.4 ± 0.9ab 8.6 ± 0.7b
Leptin (ng/mL) 4.4 ± 1.3a 11.4 ± 2.5b 6.1 ± 0.8a 13.4 ± 1.3b
Adiponectin (lg/mL/g WAT) 2.0 ± 0.2a 2.9 ± 0.1b 1.6 ± 0.1c 2.8 ± 0.1b
Insulin (lg/L) 2.4 ± 0.5 3.2 ± 0.5 3.7 ± 0.5 2.9 ± 0.6
Different superscript letters indicate significant statistical differences, ANOVA p \ 0.05, n = 9, hormones; n = 4–7 (difference in n due loss of
samples when kits were re-run with proper dilution). Adiposity index [(subcutaneous ? retroperitoneal ? inguinal fat pads)/eviscerated body
weight 9 100]
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obesogenic by inclusion of 8 en% LNA, subsequently
stimulating excessive endocannabinoid activity in the liver
and weight gain. In the present study we report that iso-
calorically increasing dietary LNA from 1 to 8 en% ele-
vated tissue levels ARA–PL, liver 2-AG and AEA
regardless of changes in total dietary fat, and increased
feed efficiency, caused higher weight gain and elevated
plasma leptin in mice fed the LFD. We also observed a
tendency of increased cell size and macrophage infiltration
in eWAT in mice fed 8 en% LNA.
The percent of n-6 in HUFA can be used as an indicator
of disease risk as it models the relative amounts of tissue
ARA–PL available as precursors for eicosanoid derivatives
of ARA [28]. We used the Lands equation [25] to predict
tissue ARA–PL composition as the % n-6 HUFA from
dietary intakes of n-6 and n-3 PUFA to model availability
of endocannabinoid precursors with good concurrence
between calculated and experimental values. Here we
modeled the increase in US dietary intakes of LNA from 1
to 8 en% [23] in our animal diets, and showed in mice, that
elevating dietary LNA to 8 en% increased ARA–PL in
liver, RBC and adipose tissue to levels currently found in
Americans [29], and induced elevations in liver 2-AG and
AEA. Elevating endocannabinoid levels by dietary LNA to
alter the availability of ARA in the phospholipid precursor
pool is consistent with several studies where dietary fatty
acids alter endocannabinoid levels [30–36], and our pre-
vious work where we selectively altered LNA and raised
dietary omega-3 HUFA both in mice and salmon [14, 15].
We did not observe any differences in food intake or
endocannabinoid levels in the cerebral cortex, suggesting
that the effects of increased endocannabinoid levels were
caused by effects in peripheral tissue. The adult brain is
less susceptible to dietary manipulations than the young
brain [37, 38]. The lower sensitivity of dietary LNA on
brain endocannabinoid levels compared to peripheral tis-
sues confirm that brain lipids levels are less influenced by
changes in dietary fatty acids and that this may be reflected
also in the endocannabinoids [39, 40].
Dietary LNA of 8 en%, independent of dietary fat
content, significantly elevated plasma leptin levels com-
pared to 1 en% LNA. Plasma adiponectin levels were less
affected by dietary LNA, suggesting that leptin is a more
sensitive marker of early obesity development. Mice fed an
LFD had similar plasma concentrations of adiponectin per
gram adipose tissue despite higher WAT and adiposity in
mice fed 8 en% LNA compared to 1 en% LNA. This result
suggests that mice fed a high LNA content secrete less
adiponectin per gram fat, in line with the obesity-prone
phenotype of the 8 en% LNA diet.
We find that the LFD containing 8 en% LNA signifi-
cantly increased feed efficiency compared to the 1 en%
LNA diet causing the animals to gain more weight per
calorie consumed. The increased feed efficiency and
weight gain in mice fed 8 en% LNA in the LFD resulted in
a similar body weight as mice fed 35 en% fat, significantly
higher than mice fed 1 en% LNA in an LFD. Dietary LNA
of 1 en% has been found to reverse the obesogenic prop-
erties of a high fat diet [14]. In line with previous studies,
our findings in the LFD support the notion that weight gain
involves mechanisms that depend more on the composition
of dietary fat than the total amount of fat in the diet [12, 30,
41–43]. Increased intake of LNA has been linked to
increased prevalence of obesity [26, 41] and the primary
dietary sources of LNA; soybean oil, poultry and shorten-
ing were positively correlated to increasing rates of obesity
occurring in the US during the 20th century [14]. Replacing
saturated fats with LNA-rich vegetable oil increased body
weight in veterans [44] and ARA levels in adipose tissue
were positively associated with BMI in children [45]. In
animals, vegetable oils rich in LNA (usually soybean oil;
55 % LNA, and safflower oil; 75 % LNA) elevated food
intake [14, 15, 46], induced weight gain [14, 15, 30, 41, 42,
47] and increased lipogenic enzyme activity in the liver
[10, 48]. Our findings imply that low fat diets could be
made more effective in reducing adiposity if LNA were
lowered to near 1 en%. Indeed, total dietary fat intake may
not need to be lowered if LNA is selectively lowered.
In contrast to what we previously reported [14], 1 en%
LNA in the MFD did not prevent weight gain and adiposity
compared to MFD 8 en% LNA. In the present study ani-
mals were fed the experimental diets from 6 weeks of age,
whereas in our previous study animals were exposed to the
dietary treatments from the last week of pregnancy to
17 weeks of age [14]. D’Asti et al. [49] demonstrated how
quantity and quality of maternal dietary fat during the
perinatal period directly influences neonatal metabolism,
fatty acid composition in phospholipids and sensitivity to
endocannabinoid system manipulation. Massiera et al. [50]
found a gradual transgenerational increase in adiposity in
Fig. 2 Weekly weight gain. After 16 weeks of feeding the LFD of
8 en% LNA resulted in similar weight gain as the MFD, significantly
higher than an LFD of 1 en% LNA
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mice fed a ‘‘western-like’’ diet of 35 en% fat containing
18 en% LA for four generations. Thus the adipogenic
effect of LNA appears to be higher when prenatally
exposed [14]. Additionally, in the present study, mice were
fed a standard NIH #31M diet based on soybean oil prior to
arrival at our facility (Taconic, Denmark). Calculations by
Fig. 3 Dietary LNA increase
macrophage infiltration and cell
size in adipose tissue.
(a) Immunostaining with F4/80
showed more crown-like
structures indicating
macrophage infiltration
(indicated by arrows) in eWAT
of mice fed 8 en% LNA
compared to mice fed 1 en%
LNA. (b) HE staining of iWAT.
Mice fed 8 en% LNA displayed
larger adipocyte cell size in
(a) eWAT and (b) iWAT in
both low fat (LF) and medium
fat diets (MF) compared to mice
fed 1 en% LNA. Data are
presented as min to max, line at
median, n = 2. Scale bar
100 lm
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the Lands equation [25] show that the NIH #31M diet
results in 72 % n-6 HUFA in tissue phospholipids, identi-
cal to our diets containing 8 en% LNA. Metabolic changes
such as induced lipogenesis and deposition of lipid droplets
in response to increased endocannabinoid activity have
been shown to occur before onset of obesity [10, 12, 51]. It
is possible that an already elevated endocannabinoid
activity present in the animals upon arrival to our facility
may have overridden the anti-adipogenic properties of the
1 en% LNA diet, when the MFD contained abundant car-
bohydrates [42]. The latter might be of importance as it has
been demonstrated that the obesogenic potential of diets
rich in both n-6 and n-3 PUFA is elevated by increasing the
levels of dietary carbohydrates, and thereby raising the
insulin/glucagon ratio translated into reduced cAMP sig-
naling [42, 52]. cAMP signaling has been demonstrated to
play a pivotal role in controlling the production of both
pro- and anti-adipogenic prostaglandins both in vivo and
in vitro [42]. Collectively these results illustrate the
importance of the type of fat and carbohydrates in the
background diet, and how these can influence the obeso-
genic properties of LNA. Mice fed an LFD of 8 en% LNA
started to gain considerably more weight than mice fed
1 en% LNA after 8 weeks of feeding. Thus a longer
feeding period may be necessary to wash out excessive
tissue ARA caused by the NIH #31M diet, before a bene-
ficial effect of a low LNA diet (1 en%) may occur.
Although body weight did not differ, elevated liver 2-AG
and AEA, larger adipocytes, higher macrophage accumu-
lation in WAT and elevated plasma leptin levels in mice
fed 8 en% may suggest a more obesity prone phenotype
and a higher risk of developing obesity and metabolic
complications associated with obesity compared to mice
fed same amount of fat but with only 1 en% LNA.
One of the major limitations when working with dietary
fat is to relate the observed differences to one fatty acid.
There are no inert oils which can be added to a diet to
target one single fatty acid to be different in a diet. We did
extensive analyses of various fats and oils available on the
market to establish the fatty acid profile of the products and
carefully mixed several oils to isolate LNA as controlled
variable via isocaloric replacement of saturated fat (in the
medium fat diet). It was not possible to obtain similar
content of MUFA in the low fat diets since the low fat diet
contained 8 en% fat as LA of the total of 12.5 en% fat.
Although our diets contained different amounts of SFA and
MUFA, SFA were covariable in the LFD and MUFA were
covariable in the MFD, thus strengthening our conclusion
that LNA is the major dietary fatty acid affecting endo-
cannabinoid levels and induces weight gain. If there were
other fatty acids (MUFA or SFA) that strongly influenced
endocannabinoid levels and adiposity we would expect the
differences between the dietary treatments to be less
distinct. Another limitation with our study is the absence of
endocannabinoid measurements in adipose tissue, making
it difficult to conclude if the observed elevation of endo-
cannabinoid levels in the liver is a consequence rather than
the cause of obesity. In order to establish a cause–effect
relationship between a diet induced elevation in endocan-
nabinoid levels and the observed obese phenotype in mice
fed the LFD of 8 en% LNA a follow-up study should be
carried out using a CB1 antagonist.
Reducing dietary LNA from 8 to 1 en% with a con-
comitant decrease in ALA from 1 to 0.3 en% significantly
increased EPA–PL concentrations in RBC (three-fold) and
liver, increasing the n-3 index from 5 to 8 and 9 in MFD
and LFD respectively. We have previously reported that
reducing LNA from 8 to 1 en% increased EPA and reduced
ARA in liver and RBC similarly to supplementing an
8 en% LNA diet with 1 en% EPA ? DHA [14]. Consistent
with previous reports [53–58], our results indicate that the
elongation and desaturation of ALA to EPA and DHA are
considerably more effective when dietary LNA is 1 en%.
Hence to improve tissue EPA and DHA concentrations,
reduce ARA–PL and consequently decrease endocannabi-
noid production, emphasis should be on lowering dietary
LNA in addition to dietary supplementation with EPA and
DHA. In conclusion, a dietary approach by reducing sub-
strate availability for endocannabinoid synthesis provides a
safe and preventative alternative to decrease hyperactivity
of the endocannabinoid system, and consequently decrease
or prevent obesity.
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